指南与共识肝病

EASL 2017乙型肝炎病毒感染管理临床实践指南

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
指南 / 共识 · J Hepatol · 2017-04-18

欧洲肝脏研究学会(EASL)发布2017版乙型肝炎病毒感染管理临床实践指南,将慢性HBV感染分为五期,明确治疗主要目标为通过预防疾病进展及肝癌发生来改善生存和生活质量,长期抑制HBV复制是当前治疗策略的主要终点,HBsAg清除为最佳终点。

要点

  • 慢性HBV感染分为五期:HBeAg阳性慢性感染、HBeAg阳性慢性肝炎、HBeAg阴性慢性感染、HBeAg阴性慢性肝炎和HBsAg阴性期。
  • 典型治疗指征为HBV DNA >2,000IU/ml、ALT升高和/或至少中度组织学病变;所有可检测到HBV DNA的肝硬化患者均应治疗。
  • 长期使用高耐药屏障的强效核苷(酸)类似物(恩替卡韦、替诺福韦二吡呋酯或替诺福韦艾拉酚胺)是首选治疗。

核心结论

  • 治疗的主要目标是通过预防疾病进展及由此导致的肝癌发生来改善生存和生活质量,长期抑制HBV复制是当前治疗策略的主要终点,HBsAg清除为最佳终点。

研究设计与样本

  • 欧洲肝脏研究学会(EASL)制定的临床实践指南,纳入HBV感染管理的最新推荐。

主要发现

  • 慢性HBV感染分为五期:HBeAg阳性慢性感染、HBeAg阳性慢性肝炎、HBeAg阴性慢性感染、HBeAg阴性慢性肝炎和HBsAg阴性期。
  • 所有慢性HBV感染者进展为肝硬化和肝细胞癌的风险均增加,取决于宿主和病毒因素。
  • 妊娠期高病毒载量孕妇需预防母婴传播,接受免疫抑制或化疗的患者需预防HBV再激活。

关键数值与推荐

  • 典型治疗指征要求HBV DNA >2,000IU/ml、ALT升高和/或至少中度组织学病变。
  • 所有可检测到HBV DNA的肝硬化患者均应治疗。
  • 推荐长期使用高耐药屏障的强效核苷(酸)类似物,即恩替卡韦、替诺福韦二吡呋酯或替诺福韦艾拉酚胺。
  • 聚乙二醇干扰素α可考虑用于轻至中度慢性乙型肝炎患者。
  • 不普遍推荐联合治疗。

临床怎么用

  • 所有患者均应监测疾病进展和肝细胞癌风险。
  • 接受治疗的患者应监测治疗应答和依从性。
  • 肝细胞癌仍是接受治疗的慢性乙型肝炎患者的主要关切。
  • 部分HBV感染亚组患者需要特别关注。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while HBsAg loss is an optimal endpoint. The typical indication for treatment requires HBV DNA >2,000IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Additional indications include the prevention of mother to child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. Pegylated interferon-alfa treatment can also be considered in mild to moderate chronic hepatitis B patients. Combination therapies are not generally recommended. All patients should be monitored for risk of disease progression and HCC. Treated patients should be monitored for therapy response and adherence. HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017. PMID: 28427875. doi:10.1016/j.jhep.2017.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。